FDA Panels to Review ‘Tamper-Resistant’ Oxycodone

FDA staff reviewers have given a tepid endorsement to a new, purportedly more tamper-resistant formulation of Purdue Pharma’s controlled-release oxycodone hydrochloride (OxyContin).

Related posts:

1. FDA Panel Recommends Approval of New Oxycodone Formulation
2. Sudden worldwide increase in antibiotic-resistant bacterium, a cause for concern
3. FDA extends Exalgo NDA review by three months